Skip to content

K-Stock Briefing

https://kstockbriefing.com

  • About Us
  • Daily Feed
  • IR Room
  • RESEARCH
  • Disclosures
    • Semiconductors
    • Energy
    • Robotics
    • Bio & Healthcare
  • Toggle search form

[Disclosure] Samsung Biologics(207940) Sets July 29 as Record Date to Determine Voting Shareholders for Extraordinary General Meeting

Posted on July 14, 2025July 13, 2026 By K-STOCK Editor No Comments on [Disclosure] Samsung Biologics(207940) Sets July 29 as Record Date to Determine Voting Shareholders for Extraordinary General Meeting

Fact Source: Financial Supervisory Service DART / 2025-07-14

Disclosure Type: Setting of Shareholder Register Closing Period or Record Date

💡 3-Second Summary

Samsung Biologics has officially announced that it has designated July 29, 2025, as the shareholder record date to finalize the list of eligible voters for its upcoming Extraordinary General Meeting of Shareholders.

📊 1. [Key Disclosure Content & Summary of Financial Figures]

  • Company Name: Samsung Biologics Co., Ltd. (207940)
  • Record Date: July 29, 2025
  • Share Transfer Suspension (Book Closure) Period: Not Applicable (Start and end dates are left blank)
  • Reason for Setting: Determination of eligible shareholders for an upcoming Extraordinary General Meeting of Shareholders
  • Other Material Terms:
    • This measure is based on Article 354 of the Commercial Act and Article 14 of the corporate Articles of Incorporation.
    • Following the enforcement of the “Act on Electronic Registration of Stocks, Bonds, etc.,” setting a formal book closure period is unnecessary for electronically registered shares; hence, the share transfer suspension period was omitted.

📈 2. [Expert Insight: What This Disclosure Means for Investors]

This filing represents a routine procedural announcement regarding corporate governance timelines rather than detailing adjustments to financial performance metrics or core operational fundamentals (Fundamental). Consequently, its direct implication on short-term market pricing remains limited.

For global market participants, the analytical value of this document lies in verifying the specific deadline and timeline to secure voting eligibility for the upcoming shareholder resolutions. Shareholders must hold the underlying stock as of the stated record date of July 29, 2025, to exercise their voting rights during the meeting. Given that the filing cross-references the “2025-05-22 Decision on Corporate Split,” it is confirmed that this registry targeting is a preliminary step geared toward voting on the restructuring plan. Since the traditional share transfer suspension period is bypassed under electronic registry regulations, investors should focus on tracking upcoming separate notices detailing the definitive date and agenda items of the scheduled general meeting.

📝 Editor’s Comment (by K-STOCK Editor)

Samsung Biologics has formalized July 29 as the definitive record date to lock in the voting block for its next Extraordinary General Meeting. While this administrative disclosure is a standard compliance routine, the linked historical filings indicate that this register alignment is a required step before voting on the proposed corporate split. Thanks to modern electronic registration laws, investors do not have to worry about trading freezes or liquidity pauses during this process. Long-term stakeholders intending to exercise corporate governance oversight should keep this late July timeline on their radar and await the upcoming detailed agenda descriptions.

📢 Disclaimer & Source Information

Source: This content has been structured and newly generated based on the official data submitted to the Financial Supervisory Service electronic disclosure system (DART).

Investment Risk Notice: This information is provided solely for informational and linguistic reference purposes. Under no circumstances does it constitute financial advice or a recommendation to buy or sell any specific stock. All investment decisions and financial responsibilities rest entirely with the investor.

Contact: For compliance inquiries or copyright requests, please contact ksb220805@gmail.com.

🐂
BULLS
VS
🐻
BEARS

🔥 Bulls vs Bears, drop your analysis in the comments!

Disclosures, Bio & Healthcare

Post navigation

Previous Post: [Disclosure] Samsung Electro-Mechanics (009150) Schedules Q2 Earnings Release for 2025.07.31
Next Post: [Disclosure] Hana Micron (067310) Extraordinary Meeting Approves Corporate Spin-off Plan; Resolution to Amend Articles of Incorporation Defeated

Related Posts

[Disclosure] SAMSUNG BIOLOGICS(207940) Secures KRW 737.3B Large-Scale CMO Contract with U.S.-Based Pharmaceutical Company Disclosures
[Disclosure] Samsung Biologics (207940) Amends U.S. Pharma Contract Value Upward to KRW 835.6B Disclosures
[Disclosure] Alteogen (196170) Postpones Expected Date of Acquiring Altos Biologics Shares to Dec 31 Due to Schedule Adjustments in Subsidiary Merger Disclosures
[Disclosure] SAMSUNG BIOLOGICS(207940) Approves FY2024 Financial Statements and Elects Yoo Seung-ho & Lee Ho-seung as New Directors at AGM Disclosures
[Disclosure] Alteogen (196170) Signs Exclusive License Agreement with AstraZeneca Subsidiary for ALT-B4 Valued up to USD 750M (KRW 1.09T) Disclosures
[Disclosure] Alteogen (196170) to Receive USD 25,000,000 (Approx. KRW 35.05B) Milestone Technical Fee from MSD for ALT-B4 Disclosures

Leave a Reply Cancel reply

You must be logged in to post a comment.

  • [Disclosure] SK square(402340), Subsidiary SK hynix Finalizes KRW 40T Paid-in Capital Increase with 2.72% PremiumJuly 10, 2026
  • [Disclosure] SK square(402340), Subsidiary SK hynix Finalizes Nasdaq Listing and 177.9M ADR Issuance VolumeJuly 10, 2026
  • [Disclosure] SK square(402340), Subsidiary SK hynix Confirms Nasdaq Listing and KRW 40T ADR Issuance TermsJuly 10, 2026
  • [Disclosure] SK Hynix(000660) Finalizes Terms for KRW 40 Trillion Paid-in Capital Increase Linked to Nasdaq ADRs (Issued at 2.72% Premium)July 10, 2026
  • [Disclosure] SK Hynix(000660) Finalizes Pricing and Timeline Terms for US Nasdaq ADR Issuance and Overseas ListingJuly 10, 2026

Copyright © 2026 K-Stock Briefing.

Powered by PressBook Grid Dark theme